IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the FirmAccesswire • 03/21/24
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the FirmAccesswire • 03/20/24
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingGlobeNewsWire • 03/19/24
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGMBusiness Wire • 03/13/24
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the FirmAccesswire • 03/12/24
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/11/24
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/11/24
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings SeasonZacks Investment Research • 03/07/24
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to ShareholdersBusiness Wire • 02/26/24
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPGlobeNewsWire • 02/26/24
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceGlobeNewsWire • 01/17/24
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®GlobeNewsWire • 11/13/23
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/02/23
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/02/23
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®GlobeNewsWire • 10/11/23
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/03/23
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/03/23
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/04/23
NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/27/23
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/01/23
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 02/28/23